UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, I ...

Financial Data and Key Metrics Changes - Net sales for Q1 2020 were $571.6 million, a 3.2% increase from $554 million in Q1 2019, with a 4.3% increase on a currency neutral basis [15] - Reported gross margin for Q1 2020 was 55.5%, down from 56.3% in Q1 2019, primarily due to a prior year's escrow release [22] - Reported net income for Q1 2020 was $685.9 million, with diluted earnings per share of $22.72, a decrease attributed to the valuation of Sartorius Holdings [25] - Non-GAAP net income for Q1 2020 was $57.6 million, or $1.91 diluted earnings per share, compared to $49.6 million and $1.65 per share in Q1 2019 [29] Business Line Data and Key Metrics Changes - Life Science Group sales were $227.2 million, a 5.3% increase from $215.7 million in Q1 2019, driven by strong demand for PCR and Droplet Digital PCR products [17] - Clinical Diagnostics sales were $343 million, a 1.9% increase from $334.1 million in Q1 2019, with growth in blood typing and quality controls offset by declines in diabetes and immunology product lines [19][20] Market Data and Key Metrics Changes - Sales in all regions were impacted by COVID-19, with demand tapering in the U.S. and Europe late in the quarter [15] - Life Science sales grew in Asia and Europe on a currency neutral basis, with growth in the Americas when excluding Process Media [19] Company Strategy and Development Direction - The company is focused on maintaining employee safety, ensuring product supply continuity, and progressing on core strategies amid the pandemic [9][12] - The recent acquisition of Celsee for $100 million aims to enhance capabilities in single-cell analysis, indicating a strategic focus on expanding technological applications [31][55] Management's Comments on Operating Environment and Future Outlook - Management withdrew annual guidance due to uncertainties from COVID-19, expecting Q2 sales to decline by 10% to 15% but anticipating recovery in the second half of the year [33] - The company continues to monitor demand and supply indicators, emphasizing a disciplined approach to expenses and operational adjustments [45] Other Important Information - The company has implemented cost-saving initiatives, resulting in SG&A expenses decreasing to 33.9% of sales from 37.5% in Q1 2019 [23] - The adjusted EBITDA for Q1 2020 was $107.4 million, or 18.8% of sales, compared to $101.7 million, or 18.4% in Q1 2019 [32] Q&A Session Summary Question: What is Bio-Rad's strategy in the serology antibody test market? - Management highlighted the platform's open system as a key differentiator, suitable for medium-sized labs and complementary to high-throughput systems [36] Question: How does the company view the impact of COVID-19 on Q2 revenue? - Management indicated that the return to work and demand for core PCR instruments will be significant factors in Q2 revenue, with ongoing monitoring of elective surgeries and clinic visits [40][41] Question: What measures are being taken to maintain margins amid revenue pressure? - The company is closely monitoring demand versus supply and has implemented cost-saving measures, including reduced discretionary spending [44][45] Question: What is the expected growth for the blood typing business? - Management expects a return to normalcy in blood typing as elective surgeries resume, although the market is generally slow-growing [47] Question: Can you elaborate on the Celsee acquisition objectives? - The acquisition is aimed at enhancing capabilities in single-cell analysis, with a focus on expanding applications in transcriptomic and genomic studies [55]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its ch ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2019 Earnings Conference Call February 13, 2020 5:00 PM ET Company Participants Ron Hutton - Vice President & Treasurer Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President & Chief Financial Officer Andy Last - Executive Vice President & Chief Operating Officer Annette Tumolo - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Dan Leonard - Wells Far ...

BIO RAD Bio-Rad Laboratories, Inc. J.P. Morgan 2020 Healthcare Conference Forward-Looking Statements Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding our performance in high growth emerging markets, continuing innovation and new products and technologies, our new focus on lab to clinic solutions, continuing and emerging leadership positions in various markets, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIE ...

Bio Rad Laboratories, Inc. (NYSE:BIO) Q3 2019 Earnings Conference Call October 31, 2019 5:00 PM ET Company Participants Ronald Hutton - VP & Treasurer Ilan Daskal - EVP & CFO Norman Schwartz - Chairman, CEO & President Andrew Last - EVP & COO Annette Tumolo - EVP & President, Life Science Group John Hertia - EVP & President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Jack Meehan - Barclays Bank Operator Ladies and gentlemen, thank you for standing by, and welcome t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, IN ...

Bio Rad Laboratories (NYSE:BIO) Q2 2019 Earnings Conference Call August 1, 2019 5:00 PM ET Company Participants Ronald Hutton - VP & Treasurer Ilan Daskal - EVP & CFO Norman Schwartz - Chairman, CEO & President Andrew Last - EVP & COO Annette Tumolo - EVP & President of Life Science Group John Hertia - EVP & President, Clinical Diagnostics Group Conference Call Participants Patrick Donnelly - Goldman Sachs Group Mitchell Petersen - Barclays Bank Daniel Leonard - Deutsche Bank Brandon Couillard - Jefferies O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-1381833 ...